Views & Analysis Future prospects for an Innovative Medicines Fund for Englan... On the 12 December 2019, the UK general public voted for a further five years of Conservative government.
News New price gets Clovis’ PARP inhibitor on the CDF NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p
Views & Analysis NICE’s track record in cancer drugs: the impact of the CDF a... Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 and CDF 2.0 to explore it's success.
Views & Analysis Pharma’s new ‘sensible pricing’ behind cancer drug approvals... A string of 'yes' decisions from NICE on cancer drugs - but what has changed?
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
